Teva Receives Positive Feedback on Second AOK Tender in Germany
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced that it has received notification from Allgemeinen Ortskrankenkassen (AOK), Germany's largest health insurance company, on the results of the most recent tender for finished dosage pharmaceutical products. Teva is very pleased to have been awarded a significant increase in the number of molecules for which it can contract to supply during 2008-2009; compared to the six products it was awarded in the first tender earlier this year.
Read more ...
InferMed appoints Cancer Research UK's Dr Sally Burtles as Observer to the Board
InferMed, a leading provider of advanced software solutions for clinical research and practice, has appointed Dr Sally Burtles, Director of Drug Development at Cancer Research UK, as an Observer to the Board.
InferMed has a long-standing relationship with Cancer Research UK, and was backed by the charity at its formation in 1999. A research relationship continues with Cancer Research UK, which remains InferMed's largest institutional shareholder.